Clinical trial · Interventional
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection：A Randomized Controlled Study
NCT02588755CI-TRIAL-00021559unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intrahepatic Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE | Procedure | — | UNRESOLVED |
| TACE+Tegafur | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- TACE+ Tegafur
- description
- Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
- interventionNames
- Procedure: TACE+Tegafur
- type
- EXPERIMENTAL
- label
- TACE
- description
- Patients will be treated with TACE alone in 4 or 8 weeks after resection.
- interventionNames
- Procedure: TACE
Primary outcomes (1)
- measure
- Overall survival rates of each group
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patients \> 18 years and \<=70 years of age. * Pathological evidence of ICC * Tumors can be completely resected. * Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. * Patients who can understand this trial and have signed information consent. Exclusion Criteria: * Tumors can not be resected . * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of Intrahepatic cholangiocarcinoma. * Patients with a medical history of other malignant tumors. * Subjects participating in other clinical trials. * Liver function:Child C.
References
Publications (0)
Data not yet available
No reference posted for this study.